A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

The use of rituximab, an anti-CD20 mAb, in combination with chemotherapy is the current standard for the treatment of B-cell lymphomas. However, because of a significant number of treatment failures, there is a demand for new, improved therapeutics. Here, we designed a nanomedicine that crosslinks C...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Te-Wei, Zhang, Rui, Yang, Jiyuan, Chao, Mark P., Shami, Paul J., Kopeček, Jindřich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440441/
https://www.ncbi.nlm.nih.gov/pubmed/26000056
http://dx.doi.org/10.7150/thno.12040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440441/
https://www.ncbi.nlm.nih.gov/pubmed/26000056
http://dx.doi.org/10.7150/thno.12040

Ejemplares similares